Moderna Posts $162M Profit, Raises Outlook as Cancer Vaccine Phase 3 Data Published and GSK Patent Dispute Settled
· techtimes.com · popularity 18/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at techtimes.com →
Summary
Moderna posts $162M Q3 profit, raises full-year guidance to 15–25% as cancer vaccine Phase 3 data confirm 42% melanoma recurrence cut and GSK patents cleared.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 10.